Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15914379 | 1.00 | MEN1 (0.56) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL10704936 | 1.00 | MEN1 (0.56) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL9731947 | 1.00 | MEN1 (0.56) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL15914347 | 0.98 | KMT2A (0.53) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL20764819 | 0.95 | MEN1 (0.53) | MEN1KMT2AKDM4CHPGDPOLB | |
| SCHEMBL9788 | 0.95 | MEN1 (0.53) | MEN1KMT2AKDM4CHPGDPOLB | |
| SCHEMBL11539684 | 0.90 | MEN1 (0.48) | MEN1KMT2AKDM4CPOLBLMNA | |
| SCHEMBL18350198 | 0.89 | MEN1 (0.57) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL4100095 | 0.87 | MEN1 (0.59) | MEN1KMT2AKDM4CTP53HPGD | |
| SCHEMBL5118077 | 0.87 | MEN1 (0.59) | MEN1KMT2AKDM4CTP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3835289-A1 | SULFUR-CONTAINING POLYMERIZABLE MONOMER AND USE THEREOF | Sun Medical Co., Ltd. (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-9126981-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | PRISM BIOLAB CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | MEN1 2962/4885KMT2A 1322/4885KDM4C 1681/4885 |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | MEN1 2962/4885KMT2A 1322/4885KDM4C 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.